Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X
- PMID: 10326170
- PMCID: PMC6656278
- DOI: 10.1002/clc.4960220513
Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X
Abstract
Background: Syndrome X is defined as typical angina pectoris, positive treadmill exercise test, negative intravenous ergonovine test, and angiographically normal coronary arteries.
Hypothesis: In the present study, we investigated the anti-ischemic and antianginal effects of nisoldipine and ramipril in patients with syndrome X.
Methods: After 2 weeks of the first wash-out period, 18 patients (7 men, 11 women, age 46 +/- 10 years) were given nisoldipine (NIS) 5 mg twice daily for 4 weeks, and after 2 weeks of the second wash-out period, the same patients were given ramipril (RAM) 2.5 mg once daily for 4 weeks. A treadmill exercise test with modified Bruce protocol was performed at the end of each period.
Results: The time to angina in exercise (607 +/- 115 s-650 +/- 117 s, p = 0.006, vs. 630 +/- 114 s-660 +/- 123 s, p = 0.02), total exercise time (612 +/- 110 s-656 +/- 114 s, p = 0.0008, vs. 630 +/- 114 s-660 +/- 123 s, p = 0.02), and maximum MET value (11.09 +/- 2.08-11.86 +/- 2.04, p = 0.0016, vs. 11.42 +/- 2.09-12.2 +/- 2.26, p = 0.01) were increased significantly with both therapy modalities. The time to 1 mm ST-segment depression (123 +/- 93 s-220 +/- 172 s, p = 0.002) was increased significantly with NIS therapy. The time to ST-segment recovery (434 +/- 268 s-330 +/- 233 s, p = 0.016 vs. 443 +/- 289 s-370 +/- 278 s, p = 0.012), the frequency of anginal attacks per week (1.27 +/- 1.4-0 +/- 0.38, p = 0.005, vs. 1 +/- 1.32-0.33 +/- 0.59, p = 0.028), and the need for sublingual nitroglycerin (1.16 +/- 1.29-0.11 +/- 0.32, p = 0.005, vs. 0.94 +/- 1.16-0.27 +/- 0.57, p = 0.012) were decreased significantly with both drugs.
Conclusion: We observed that 10 mg daily NIS and 2.5 mg daily RAM have similar anti-ischemic and antianginal effects in patients with syndrome X.
Similar articles
-
Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial.Zhonghua Yi Xue Za Zhi (Taipei). 1996 Nov;58(5):323-8. Zhonghua Yi Xue Za Zhi (Taipei). 1996. PMID: 9037847 Clinical Trial.
-
Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris.Circulation. 1991 Dec;84(6):2398-408. doi: 10.1161/01.cir.84.6.2398. Circulation. 1991. PMID: 1959195 Clinical Trial.
-
Protective effect of nisoldipine on dipyridamole-induced myocardial ischemia: correlation with exercise electrocardiography.Coron Artery Dis. 1998;9(4):207-15. doi: 10.1097/00019501-199809040-00006. Coron Artery Dis. 1998. PMID: 9649927
-
Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.Drugs. 1997 May;53(5):867-84. doi: 10.2165/00003495-199753050-00013. Drugs. 1997. PMID: 9129871 Review.
-
Nisoldipine CC: clinical experience in ischaemic heart disease.Cardiology. 1997;88 Suppl 1:17-23; discussion 24-5. doi: 10.1159/000177454. Cardiology. 1997. PMID: 9118164 Review.
Cited by
-
Microvascular angina: angina that predominantly affects women.Korean J Intern Med. 2015 Mar;30(2):140-7. doi: 10.3904/kjim.2015.30.2.140. Epub 2015 Feb 27. Korean J Intern Med. 2015. PMID: 25750553 Free PMC article. Review.
-
[Coronary microvascular dysfunction : Clinical aspects, diagnosis and therapy].Herz. 2016 Jun;41(4):351-60. doi: 10.1007/s00059-016-4439-z. Herz. 2016. PMID: 27255117 Review. German.
-
Treatment Modalities for Angina with Non-Obstructive Coronary Arteries (ANOCA): A Systematic Review and Meta-Analysis.J Clin Med. 2025 Jun 9;14(12):4069. doi: 10.3390/jcm14124069. J Clin Med. 2025. PMID: 40565817 Free PMC article. Review.
-
Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition).MedComm (2020). 2023 Dec 19;4(6):e438. doi: 10.1002/mco2.438. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 38116064 Free PMC article. Review.
-
Recent developments in microvascular angina.Curr Atheroscler Rep. 2001 Mar;3(2):149-55. doi: 10.1007/s11883-001-0051-6. Curr Atheroscler Rep. 2001. PMID: 11177659 Review.
References
-
- Maseri A, Crea F, Kaski JC, Crake T: Mechanisms of angina pectoris in syndrome X. J Am Coll Cardiol 1991; 17: 499–506 - PubMed
-
- Lanza GA, Manzoli A, Bia E, Crea F, Maseri A: Acute effects of nitrates on exercise testing in patients with syndrome X. Circulation 1994; 90: 2695–2700 - PubMed
-
- Cianflone D, Lanza GA, Maseri A: Microvascular angina in patients with normal coronary arteries and with other ischaemic syndromes. Eur Heart J 1995; 16 (suppl I): 96–103 - PubMed
-
- Cannon RO, Leon MB, Watson RM, Rosing DR, Epstein SE: Chest pain and normal coronary arteries. Role of small coronary arteries. Am J Cardiol 1986; 58: 53–59 - PubMed
-
- Cannon RO, Epstein SE: “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 1988; 61: 1338–1343 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous